Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: Analysis of its use in 427 cancer patients

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: In the past few years, several studies have been performed to evaluate thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVC), but the analysis of these studies does not allow firm conclusions to be drawn. Patients and Methods: Four hundred and twenty-seven cancer patients were evaluated. Each received warfarin at a dose of 1 mg/daily as prophylaxis, starting the day after CVC positioning until its removal. Results: The catheters were monitored for a mean of 168 days (range 22-706). There were 9 thrombotic events (1.8%). Overall, International Normalised Ratio (INR) elevation occurred in 55 (12.8%) patients. Bleeding was observed in 15 (3.5%) patients, 10 of whom had elevated INR levels. Of these, all were treated with continuous-infusion 5-Fluorouracil (5-FU)-based regimens. Conclusion: Minidose warfarin can protect from clinical thrombosis, but can induce an alteration in INR values and/or haemorrhagic symptoms in patients being treated with 5-FU-based regimens.

Original languageEnglish
Pages (from-to)3143-3148
Number of pages6
JournalAnticancer Research
Volume25
Issue number4
Publication statusPublished - Jul 2005

Fingerprint

Upper Extremity Deep Vein Thrombosis
Warfarin
International Normalized Ratio
Neoplasms
Central Venous Catheters
Fluorouracil
Thrombosis
Catheters
Hemorrhage

Keywords

  • Catheters
  • Chemotherapy
  • Prophylaxis
  • Thrombosis
  • Warfarin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{68913bf1e5f14a1d87e62a8d9d91dde3,
title = "Prophylaxis of central venous catheter-related thrombosis with minidose warfarin: Analysis of its use in 427 cancer patients",
abstract = "Background: In the past few years, several studies have been performed to evaluate thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVC), but the analysis of these studies does not allow firm conclusions to be drawn. Patients and Methods: Four hundred and twenty-seven cancer patients were evaluated. Each received warfarin at a dose of 1 mg/daily as prophylaxis, starting the day after CVC positioning until its removal. Results: The catheters were monitored for a mean of 168 days (range 22-706). There were 9 thrombotic events (1.8{\%}). Overall, International Normalised Ratio (INR) elevation occurred in 55 (12.8{\%}) patients. Bleeding was observed in 15 (3.5{\%}) patients, 10 of whom had elevated INR levels. Of these, all were treated with continuous-infusion 5-Fluorouracil (5-FU)-based regimens. Conclusion: Minidose warfarin can protect from clinical thrombosis, but can induce an alteration in INR values and/or haemorrhagic symptoms in patients being treated with 5-FU-based regimens.",
keywords = "Catheters, Chemotherapy, Prophylaxis, Thrombosis, Warfarin",
author = "Massimo Magagnoli and Giovanna Masci and Luca Castagna and Zucali, {Paolo Andrea} and Emanuela Morenghi and Vittorio Pedicini and Armando Santoro",
year = "2005",
month = "7",
language = "English",
volume = "25",
pages = "3143--3148",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Prophylaxis of central venous catheter-related thrombosis with minidose warfarin

T2 - Analysis of its use in 427 cancer patients

AU - Magagnoli, Massimo

AU - Masci, Giovanna

AU - Castagna, Luca

AU - Zucali, Paolo Andrea

AU - Morenghi, Emanuela

AU - Pedicini, Vittorio

AU - Santoro, Armando

PY - 2005/7

Y1 - 2005/7

N2 - Background: In the past few years, several studies have been performed to evaluate thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVC), but the analysis of these studies does not allow firm conclusions to be drawn. Patients and Methods: Four hundred and twenty-seven cancer patients were evaluated. Each received warfarin at a dose of 1 mg/daily as prophylaxis, starting the day after CVC positioning until its removal. Results: The catheters were monitored for a mean of 168 days (range 22-706). There were 9 thrombotic events (1.8%). Overall, International Normalised Ratio (INR) elevation occurred in 55 (12.8%) patients. Bleeding was observed in 15 (3.5%) patients, 10 of whom had elevated INR levels. Of these, all were treated with continuous-infusion 5-Fluorouracil (5-FU)-based regimens. Conclusion: Minidose warfarin can protect from clinical thrombosis, but can induce an alteration in INR values and/or haemorrhagic symptoms in patients being treated with 5-FU-based regimens.

AB - Background: In the past few years, several studies have been performed to evaluate thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVC), but the analysis of these studies does not allow firm conclusions to be drawn. Patients and Methods: Four hundred and twenty-seven cancer patients were evaluated. Each received warfarin at a dose of 1 mg/daily as prophylaxis, starting the day after CVC positioning until its removal. Results: The catheters were monitored for a mean of 168 days (range 22-706). There were 9 thrombotic events (1.8%). Overall, International Normalised Ratio (INR) elevation occurred in 55 (12.8%) patients. Bleeding was observed in 15 (3.5%) patients, 10 of whom had elevated INR levels. Of these, all were treated with continuous-infusion 5-Fluorouracil (5-FU)-based regimens. Conclusion: Minidose warfarin can protect from clinical thrombosis, but can induce an alteration in INR values and/or haemorrhagic symptoms in patients being treated with 5-FU-based regimens.

KW - Catheters

KW - Chemotherapy

KW - Prophylaxis

KW - Thrombosis

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=22944486343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944486343&partnerID=8YFLogxK

M3 - Article

C2 - 16080578

AN - SCOPUS:22944486343

VL - 25

SP - 3143

EP - 3148

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -